(Q40754903)

23 September 2017

title

Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study (English)

1 reference

23 September 2017

1 reference

1

G Fountzilas

1 reference

23 September 2017

C Nicolaides

2

1 reference

23 September 2017

D Bafaloukos

3

1 reference

23 September 2017

A Kalogera-Fountzila

4

1 reference

23 September 2017

H Kalofonos

5

1 reference

23 September 2017

G Samelis

6

1 reference

23 September 2017

G Aravantinos

7

1 reference

23 September 2017

N Pavlidis

8

1 reference

23 September 2017

publication date

1 January 2000

1 reference

23 September 2017

1 reference

23 September 2017

volume

18

1 reference

23 September 2017

issue

6

1 reference

23 September 2017

page(s)

503-509

1 reference

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07357900009012188

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009012188

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009012188

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009012188

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009012188

A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009012188

Advanced breast cancer: a phase II trial with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009012188

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009012188

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009012188

Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009012188

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009012188

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009012188

10.3109/07357900009012188

21 January 2018

Identifiers

DOI

1 reference

23 September 2017

1 reference